Online inquiry

IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ1025MR)

This product GTTS-WQ1025MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	Pseudo-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_000245.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	4233
UniProt ID	P08581

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1025MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ1120MR	IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	ABBV-927
GTTS-WQ14906MR	IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	Shigamabs®
GTTS-WQ5765MR	IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	CetuxiMab-GEX
GTTS-WQ5228MR	IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	CB 2679d
GTTS-WQ14158MR	IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	aIL6R88
GTTS-WQ14188MR	IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	REGN-910
GTTS-WQ8725MR	IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	HuPRO-140
GTTS-WQ11603MR	IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	MGD-006

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST